SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 25.65+2.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Chris Boylan who wrote (9001)3/8/1999 5:39:00 PM
From: Bluegreen  Read Replies (3) of 17367
 
You said>>>>>>>>>>>>>>Wrong. If they have as an end-point reduced morbidity, they need
a certain number of people to die in order to have statistically
valid results if they are going to go before the FDA AC and make
an efficacy claim with regard to morbidity.<<<<<
You don't need any kids to die to prove up reduced morbidity. One of the goals of this trial was to wait until a certain mortality figure was reached cumulative of both placebo and treated groups. It might interest you to know that historically speaking, administering Neuprex in Meningo. INCREASES morbidity. Hard to see how you can be long using your posts as a guide. It looks as though you just jumped in with some off the cuff ramblings.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News